Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Animals
Antigens, Neoplasm
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Cytotoxicity, Immunologic
Disease Models, Animal
Female
GPI-Linked Proteins
/ genetics
Gene Expression
Gene Expression Profiling
Genetic Engineering
HLA-A Antigens
/ genetics
Humans
Immunophenotyping
Immunotherapy, Adoptive
/ adverse effects
Mesothelin
Mice
Neoplasm Grading
Neoplasm Staging
Ovarian Neoplasms
/ genetics
Prognosis
Receptors, Antigen, T-Cell
/ genetics
Receptors, Chimeric Antigen
/ genetics
T-Lymphocytes
/ immunology
Treatment Outcome
Xenograft Model Antitumor Assays
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
09
04
2019
revised:
29
05
2019
accepted:
19
07
2019
pubmed:
25
7
2019
medline:
8
9
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian cancer (HGSOC) patients. Ovarian tumors develop a hostile, multicomponent tumor microenvironment containing suppressive cells, inhibitory ligands, and soluble factors that facilitate evasion of antitumor immune responses. Developing and validating an immunocompetent mouse model of metastatic ovarian cancer that shares antigenic and immunosuppressive qualities of human disease would facilitate establishing effective T-cell therapies. We used deep transcriptome profiling and IHC analysis of human HGSOC tumors and disseminated mouse ID8
Identifiants
pubmed: 31337659
pii: 2326-6066.CIR-19-0258
doi: 10.1158/2326-6066.CIR-19-0258
pmc: PMC6726582
mid: NIHMS1535763
doi:
Substances chimiques
Antigens, Neoplasm
0
GPI-Linked Proteins
0
HLA-A Antigens
0
Msln protein, mouse
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1412-1425Subventions
Organisme : NCI NIH HHS
ID : P01 CA018029
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA033084
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA033084
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009657
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Cell. 2015 Nov 9;28(5):638-652
pubmed: 26525103
Blood. 2017 Nov 30;130(22):2410-2419
pubmed: 29042364
Nature. 2016 Apr 28;532(7600):512-6
pubmed: 27096360
Cancer. 2015 Sep 15;121(18):3203-11
pubmed: 26096019
Oncoimmunology. 2014 Aug 03;3(8):e954471
pubmed: 25610747
J Clin Oncol. 2015 Apr 20;33(12):1325-33
pubmed: 25584002
Nature. 1986 Mar 20-26;320(6059):232-8
pubmed: 2421164
Cancer Immunol Res. 2013 Jul;1(1):26-31
pubmed: 24777247
Anticancer Res. 2006 Jul-Aug;26(4B):2785-9
pubmed: 16886597
BMC Med Genomics. 2018 Mar 27;11(1):36
pubmed: 29587858
Brief Bioinform. 2016 May;17(3):393-407
pubmed: 26342128
Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Oncotarget. 2012 Feb;3(2):114-5
pubmed: 22337812
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Dis Model Mech. 2015 Jan;8(1):1-16
pubmed: 25561744
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Gynecol Oncol. 2009 Nov;115(2):185-92
pubmed: 19665763
Clin Cancer Res. 2014 May 1;20(9):2457-65
pubmed: 24634374
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
J Immunother. 2010 Jan;33(1):1-7
pubmed: 19952961
Int J Womens Health. 2017 Dec 15;9:913-924
pubmed: 29290694
Eur J Immunol. 1987 Dec;17(12):1843-6
pubmed: 2961577
Cancer Discov. 2016 Feb;6(2):133-46
pubmed: 26503962
Immunity. 2013 Jul 25;39(1):61-73
pubmed: 23890064
Vet Immunol Immunopathol. 2013 Mar 15;152(1-2):13-9
pubmed: 23078904
Mol Immunol. 2012 Jul;51(3-4):263-72
pubmed: 22503210
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
Nat Commun. 2013;4:2126
pubmed: 23839242
Cancer Res. 2016 Oct 15;76(20):6118-6129
pubmed: 27530326
J Exp Clin Cancer Res. 2016 Mar 01;35:39
pubmed: 26931187
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
Curr Opin Oncol. 2014 Sep;26(5):492-500
pubmed: 25036883
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Curr Pathobiol Rep. 2015;3(3):219-223
pubmed: 26246962
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Nat Commun. 2017 Oct 23;8(1):1093
pubmed: 29061967
Am J Pathol. 2002 Dec;161(6):2295-309
pubmed: 12466143
Sci Rep. 2016 Jan 28;6:20070
pubmed: 26818188
Cancer Immunol Res. 2014 Feb;2(2):112-20
pubmed: 24579088